Trial Profile
Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2020
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms AtWoRC
- Sponsors Lundbeck Canada
- 15 Sep 2020 Results assessing baseline characteristics and treatment outcomes from AtWoRC following vortioxetine treatment, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology.
- 09 Oct 2018 Results presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.